The place of newer oral anticoagulants in the treatment of patients with non‐valvular atrial fibrillation and coronary artery disease

With the arrival of the newer oral anticoagulants (NOACs), we now have a more convenient means of providing anticoagulation for patients with non‐valvular atrial fibrillation (AF). Are there any particular considerations for the many patients who also have coronary artery disease? For many patients there is an obvious need to use the newer agents but for others, such as those who simply refuse to consider using a vitamin K antagonist (VKA) such as warfarin, the decision may be more problematical.